GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Float Percentage Of Total Shares Outstanding

Hepion Pharmaceuticals (FRA:336) Float Percentage Of Total Shares Outstanding : 99.82% (As of May. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hepion Pharmaceuticals's float shares is 4.33 Mil. Hepion Pharmaceuticals's total shares outstanding is 4.34 Mil. Hepion Pharmaceuticals's float percentage of total shares outstanding is 99.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hepion Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hepion Pharmaceuticals's Institutional Ownership is 7.14%.

Hepion Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Hepion Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=4.33/4.34
=99.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals (FRA:336) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ACER VINC HARP ELEV SKYE ICU CBIO PLUR UNCY ONCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HEPA:USA
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Website
https://www.hepionpharma.com
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines